R&D | January 21, 2026
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
India’s pharmaceutical sector stands at a pivotal inflection point
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Full approval will depend on verification of clinical benefit in a confirmatory trial
The company also reported significant progress toward its internally defined Sustainable Development Goals
Subscribe To Our Newsletter & Stay Updated
